HUP0302455A2 - Amlodipint és benazeprilt tartalmazó kombinációs gyógyszerkészítmények és alkalmazásuk - Google Patents

Amlodipint és benazeprilt tartalmazó kombinációs gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0302455A2
HUP0302455A2 HU0302455A HUP0302455A HUP0302455A2 HU P0302455 A2 HUP0302455 A2 HU P0302455A2 HU 0302455 A HU0302455 A HU 0302455A HU P0302455 A HUP0302455 A HU P0302455A HU P0302455 A2 HUP0302455 A2 HU P0302455A2
Authority
HU
Hungary
Prior art keywords
pharmaceutically acceptable
acceptable salt
benazepril
amlodipine
diseases
Prior art date
Application number
HU0302455A
Other languages
English (en)
Inventor
William Lionel Daley
Randy Lee Webb
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21742073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0302455(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0302455A2 publication Critical patent/HUP0302455A2/hu
Publication of HUP0302455A3 publication Critical patent/HUP0302455A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Jelen találmány egy gyógyszerkombinációra és alkalmazására vonatkozik,amely gyógyszerkombináció 1) egy ACE-gátlót, például benazeprilt,benazeprilátot vagy ezek gyógyszerészetileg elfogadható sóját, és 2)amlodipint vagy annak gyógyszerészetileg elfogadható sóját tartalmazzaa magas vérnyomás betegség, kongesztív szívelégtelenség, angina,miokardiális infarktus, ateroszklerozis, diabetikus nefropátia,diabetikus kardiomiopátia, veseelégtelenség, perifériás érbetegségek,balkamrai hipertrófia, kognitív működési elégtelenségek, vérnyomássalkapcsolatos agyi érbetegségek, agyvérzés és tüdőbetegségek vagy akisvérköri hipertenzió és a fejfájás kezelésére, vagy megelőzésére,vagy kialakulásának késleltetésre használható gyógyszerkészítményelőállítására, amely kombinációs gyógyszerkészítmény (i) az amlodipintvagy gyógyszerészetileg elfogadható sóját 6-40 mg szabad bázisnakmegfelelő mennyiségben, és (ii) az ACE-gátlót vagy gyógyszerészetilegelfogadható sóját 20-160 mg benazeprilhidrokloridnak megfelelőmennyiségben tartalmazza. Ó
HU0302455A 2000-12-18 2000-12-18 Combination pharmaceutical compositions containing amplodipine and benazepril and their use HUP0302455A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/034246 WO2002049645A1 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril

Publications (2)

Publication Number Publication Date
HUP0302455A2 true HUP0302455A2 (hu) 2003-11-28
HUP0302455A3 HUP0302455A3 (en) 2005-05-30

Family

ID=21742073

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0302455A HUP0302455A3 (en) 2000-12-18 2000-12-18 Combination pharmaceutical compositions containing amplodipine and benazepril and their use
HU0302456A HUP0302456A3 (en) 2000-12-18 2001-12-17 Combination pharmaceutical compositions containing of amlodipine and benazepril and their use and preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0302456A HUP0302456A3 (en) 2000-12-18 2001-12-17 Combination pharmaceutical compositions containing of amlodipine and benazepril and their use and preparation

Country Status (27)

Country Link
EP (3) EP1365761A1 (hu)
JP (3) JP2004516266A (hu)
KR (3) KR20040007420A (hu)
CN (2) CN1461218A (hu)
AT (1) ATE338549T1 (hu)
AU (4) AU2001225816B2 (hu)
BR (2) BR0017386A (hu)
CA (2) CA2432638A1 (hu)
CY (1) CY1106275T1 (hu)
CZ (2) CZ20031678A3 (hu)
DE (1) DE60122928T2 (hu)
DK (1) DK1345607T3 (hu)
EC (1) ECSP034658A (hu)
ES (1) ES2272565T3 (hu)
HK (1) HK1059566A1 (hu)
HU (2) HUP0302455A3 (hu)
IL (4) IL156136A0 (hu)
MX (2) MXPA03005462A (hu)
NO (2) NO20032766L (hu)
NZ (1) NZ526467A (hu)
PL (2) PL362252A1 (hu)
PT (1) PT1345607E (hu)
RU (1) RU2292206C2 (hu)
SI (1) SI1345607T1 (hu)
SK (2) SK7652003A3 (hu)
WO (2) WO2002049645A1 (hu)
ZA (1) ZA200304514B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511631A (ja) * 2001-11-23 2005-04-28 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 脳血管障害発作の急性期における高血圧症の治療
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
BRPI0409699A (pt) 2003-04-25 2006-04-18 Novacardia Inc métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
CA2542757A1 (en) * 2003-10-20 2005-04-28 Novartis Ag Use of organic compounds
WO2005074927A1 (en) * 2004-02-09 2005-08-18 Novartis Ag Therapeutic combination of amlodipine and benazepril/ benazeprilat for the treatment of hypertension
WO2005079772A2 (en) * 2004-02-18 2005-09-01 Sepracor Inc. Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US20080268049A1 (en) * 2005-02-11 2008-10-30 Dhaliwal Mona Stable Solid Dosage Forms of Amlodipine and Benazepril
WO2006092732A2 (en) * 2005-03-04 2006-09-08 Aurobindo Pharma Ltd Stable solid dosage form of antihypertensive agent
NZ561486A (en) 2005-03-15 2011-03-31 Lupin Ltd Pharmaceutical compositions of amlodipine and benazepril
PT1797885E (pt) * 2005-09-28 2008-05-20 Teva Pharma Combinações estáveis de besilato de amlodipina e cloridrato de benazepril
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
WO2007040511A1 (en) * 2005-09-28 2007-04-12 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
SE534111C2 (sv) * 2009-09-14 2011-05-03 Scania Cv Ab Metod och system för styrning av en koppling
IT1398168B1 (it) * 2010-02-16 2013-02-14 Chiesi Farma Spa Uso di ingredienti attivi in combinazione per il trattamento delle complicanze del diabete.
SI2585051T2 (sl) 2010-06-23 2020-07-31 Krka, D.D., Novo Mesto Farmacevtske oralne odmerne oblike,ki obsegajo lerkanidipin in enalapril in njune farmacevtsko sprejemljive soli
CN102389431A (zh) * 2011-09-28 2012-03-28 济南龙华医药技术有限公司 一种含有盐酸贝尼地平和盐酸贝那普利的复方制剂及其应用
PL2793866T5 (pl) * 2011-12-21 2023-12-04 Elanco Tiergesundheit Ag Tabletka dwuwarstwowa zawierająca chlorowodorek benazeprylu i pimobendan
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
JP2015529206A (ja) * 2012-08-25 2015-10-05 ザ・ジョンズ・ホプキンス・ユニバーシティ Gapdhカスケードインヒビター化合物ならびに使用の方法および精神病を含むストレス誘導障害の処置
EP3865120A1 (en) 2013-07-19 2021-08-18 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CN110721164B (zh) 2013-12-04 2024-09-17 勃林格殷格翰动物保健有限公司 匹莫苯的改善的药物组合物
KR20180123021A (ko) * 2016-03-24 2018-11-14 다이이찌 산쿄 가부시키가이샤 신질환의 치료를 위한 의약
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
TN2019000148A1 (en) 2016-11-16 2020-10-05 Abide Therapeutics Inc Pharmaceutical formulations
WO2018093953A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Crystalline forms of a magl inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
BR9604818A (pt) * 1995-04-07 1998-06-09 Novartis Ag Composições de combinação contendo benazepril ou benazeprilat e valsartan
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Also Published As

Publication number Publication date
KR20090033914A (ko) 2009-04-06
KR20030061840A (ko) 2003-07-22
JP2010043111A (ja) 2010-02-25
CZ20031677A3 (cs) 2003-10-15
CN1481241A (zh) 2004-03-10
MXPA03005463A (es) 2003-09-25
CZ301424B6 (cs) 2010-02-24
NZ526467A (en) 2005-04-29
BR0017386A (pt) 2004-01-13
AU2002232620B2 (en) 2005-11-03
EP1365761A1 (en) 2003-12-03
AU2581601A (en) 2002-07-01
ZA200304514B (en) 2004-05-10
EP1674099A1 (en) 2006-06-28
HUP0302455A3 (en) 2005-05-30
RU2292206C2 (ru) 2007-01-27
WO2002049646A1 (en) 2002-06-27
JP2004519440A (ja) 2004-07-02
HK1059566A1 (en) 2004-07-09
EP1345607A1 (en) 2003-09-24
CZ20031678A3 (cs) 2003-10-15
SK7642003A3 (en) 2003-11-04
PT1345607E (pt) 2007-01-31
IL156136A0 (en) 2003-12-23
WO2002049645A1 (en) 2002-06-27
CA2432638A1 (en) 2002-06-27
PL360989A1 (en) 2004-09-20
HUP0302456A2 (hu) 2003-11-28
NO20032766D0 (no) 2003-06-17
NO20032766L (no) 2003-08-14
BR0116228A (pt) 2003-12-30
ECSP034658A (es) 2003-07-25
SK7652003A3 (en) 2003-12-02
IL156267A0 (en) 2004-01-04
EP1345607B1 (en) 2006-09-06
IL190802A0 (en) 2008-11-03
CY1106275T1 (el) 2011-10-12
PL362252A1 (en) 2004-10-18
ES2272565T3 (es) 2007-05-01
AU3262002A (en) 2002-07-01
ATE338549T1 (de) 2006-09-15
JP2004516266A (ja) 2004-06-03
NO20032765L (no) 2003-08-14
SI1345607T1 (sl) 2007-02-28
KR20040007420A (ko) 2004-01-24
AU2001225816B2 (en) 2005-10-13
MXPA03005462A (es) 2003-09-25
HUP0302456A3 (en) 2004-05-28
DK1345607T3 (da) 2006-12-27
RU2003121019A (ru) 2005-01-20
DE60122928T2 (de) 2007-09-06
AU2002232620B9 (en) 2005-11-24
DE60122928D1 (de) 2006-10-19
CA2432282A1 (en) 2002-06-27
NO20032765D0 (no) 2003-06-17
CN1461218A (zh) 2003-12-10
IL190801A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
HUP0302455A2 (hu) Amlodipint és benazeprilt tartalmazó kombinációs gyógyszerkészítmények és alkalmazásuk
TW473394B (en) Pharmaceutical composition comprising a smaller oral dosage form of valsartan
BG104075A (en) Combined treatment including atorvastatin and an antihypertonic form
HUP0203257A2 (hu) Atorvastatin kalcium polimorf módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO20024733D0 (no) Hydrofile molekyl¶rdisperse lösninger av karvedilol
HUP0003386A2 (hu) CRF antagonisták alkalmazása depresszió, kardiovaszkuláris betegségek kezelésére szolgáló gyógyszerkészítmények előállítására
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
TR200101470T2 (tr) Farmasötik bileşim terkipleri.
HUP0105364A2 (hu) Spontán diszpergálódó N-benzoil sztaurosporint tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
HUP0300917A2 (hu) Bradikardiakumok alkalmazása hipertrófiával társult miokardiális betegségek kezelésére és ezeket tartalmazó gyógyszerkészítmények
HUP9801593A2 (hu) Benazeprilt vagy benazeprilátot és valzartánt tartalmazó kombinált gyógyszerkészítmények és azok alkalmazása
KR20090047424A (ko) 굴심방 결절 If 전류 억제제와 앤지오텐신 전환 효소 억제제의 회합체, 및 이를 함유한 약제 조성물
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
SG153644A1 (en) Therapeutic combination of amlodipine and benazepril
ATE324887T1 (de) Citalopram zur behandlung von bluthochdruck
HUP0105210A2 (hu) Moxonidin felhasználása szívizominfraktus utókezelésére
RU93010557A (ru) Средство для лечения ишемической болезни сердца

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees